Clinical Trials Search
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
The purpose of this study is to find out what effects (good and bad) AZD1775 used in combination with carboplatin and paclitaxel will have on participants and their cancer.
Primary Objective: Determine the progression-free survival of carboplatin-paclitaxel plus AZD1775 in patients with advanced/metastatic SQCLC. Secondary Objectives: 1. Estimate time-to-event variables, such as overall survival time, duration of overall response, and duration of stable disease. 2. Estimate the disease control rates (complete response, partial response, and stable disease).
AZD1775 (); MK-1775 (AZD1775); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin (); paclitaxel ()